open access

Vol 20, No 6 (2015)
Special Issue Papers
Published online: 2015-11-01
Submitted: 2014-04-23
Get Citation

Retreatment for prostate cancer with stereotactic body radiation therapy (SBRT): Feasible or foolhardy?

Stefano Arcangeli, Linda Agolli, Vittorio Donato
DOI: 10.1016/j.rpor.2014.08.001
·
Rep Pract Oncol Radiother 2015;20(6):425-429.

open access

Vol 20, No 6 (2015)
Special Issue Papers
Published online: 2015-11-01
Submitted: 2014-04-23

Abstract

The most popular therapeutic option in the management of radio-recurrent prostatic carcinoma is represented by the androgen deprivation therapy, that however should be considered only palliative and hampered by potential adverse effects of testosterone suppression. Local therapies such as surgery, cryoablation or brachytherapy might be curative choices for patients in good conditions and with a long-life expectancy, but at cost of significant risk of failure and severe toxicity. The administration of stereotactic body radiation therapy (SBRT) in this setting have come about because of tremendous technologic advances in image guidance and treatment delivery techniques that enable the delivery of large doses to tumor with reduced margins and high gradients outside the target, thereby reducing the volume of rectum which already received significant doses from primary radiotherapy. So far, very modest data are available to support its employment. Rationale, clinical experience, and challenges are herein reviewed and discussed.

Abstract

The most popular therapeutic option in the management of radio-recurrent prostatic carcinoma is represented by the androgen deprivation therapy, that however should be considered only palliative and hampered by potential adverse effects of testosterone suppression. Local therapies such as surgery, cryoablation or brachytherapy might be curative choices for patients in good conditions and with a long-life expectancy, but at cost of significant risk of failure and severe toxicity. The administration of stereotactic body radiation therapy (SBRT) in this setting have come about because of tremendous technologic advances in image guidance and treatment delivery techniques that enable the delivery of large doses to tumor with reduced margins and high gradients outside the target, thereby reducing the volume of rectum which already received significant doses from primary radiotherapy. So far, very modest data are available to support its employment. Rationale, clinical experience, and challenges are herein reviewed and discussed.

Get Citation

Keywords

Radiorecurrent prostatic carcinoma; SBRT; Spacer hydrogel

About this article
Title

Retreatment for prostate cancer with stereotactic body radiation therapy (SBRT): Feasible or foolhardy?

Journal

Reports of Practical Oncology and Radiotherapy

Issue

Vol 20, No 6 (2015)

Pages

425-429

Published online

2015-11-01

DOI

10.1016/j.rpor.2014.08.001

Bibliographic record

Rep Pract Oncol Radiother 2015;20(6):425-429.

Keywords

Radiorecurrent prostatic carcinoma
SBRT
Spacer hydrogel

Authors

Stefano Arcangeli
Linda Agolli
Vittorio Donato

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk, Poland
tel.:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: journals@viamedica.pl